By Counterforce Health Team in Zanzalintinib (XL092) [investigational] —

Getting Zanzalintinib (XL092) Covered by Humana in New Jersey: Clinical Trial Access and Compassionate Use Guide

Quick Answer: Your Path to Zanzalintinib Access in New Jersey

Zanzalintinib (XL092) is investigational and not FDA-approved, so Humana won't cover the drug itself—but you have two main paths: clinical trials (free drug) or compassionate use (free drug, insurance covers monitoring). In New Jersey, if Humana denies coverage for routine care during compassionate use, you have 65 days to appeal internally, then can file an external review through New Jersey's IHCAP program within 4 months. Start today: Search active trials at ClinicalTrials.gov or ask your oncologist about Exelixis's expanded access program.

Table of Contents

  1. Understanding Zanzalintinib Coverage Reality
  2. Clinical Trials: Your Best Option
  3. Compassionate Use Program
  4. When Humana Denies Routine Care
  5. New Jersey Appeals Process
  6. Building Your Medical Necessity Case
  7. Templates and Scripts
  8. Costs and Patient Support
  9. FAQ

Understanding Zanzalintinib Coverage Reality

Zanzalintinib (XL092) is an investigational multi-target tyrosine kinase inhibitor (TKI) developed by Exelixis. As of 2025, it has no FDA approval for any indication, meaning Humana's formulary excludes it entirely. The drug is currently being studied in multiple Phase 1, 2, and 3 trials under the STELLAR program.

Here's what this means for coverage:

Coverage Aspect Humana's Position Your Options
Drug Cost Not covered (investigational) Clinical trials or compassionate use (free)
Routine Monitoring May cover with prior authorization Appeal if denied; document medical necessity
Administration Costs Covered if medically necessary Submit PA with supporting documentation
Note: Even though Humana won't pay for the drug itself, they may still deny coverage for the medical care surrounding its use—that's where appeals become crucial.

Clinical Trials: Your Best Option

Clinical trials offer the fastest, most reliable access to Zanzalintinib with no insurance hassles. The drug and all trial-related care are provided at no cost.

Active Zanzalintinib Trials

Search ClinicalTrials.gov for current studies using terms like "zanzalintinib" or "XL092." Recent trials include:

  • NCT06571734: Multi-tumor basket study
  • NCT06191796: Combination therapy trial
  • STELLAR-303: Advanced solid tumors (verify site-specific policy for current status)

Trial Eligibility (Typical Requirements)

  • Life-threatening or seriously debilitating cancer
  • ECOG performance status 0-2
  • Adequate organ function (recent labs required)
  • Measurable disease per RECIST 1.1
  • Failed or intolerant to standard therapies

Action Step: Contact your oncologist today to discuss trial eligibility. Most major cancer centers in New Jersey participate in Exelixis trials.

Compassionate Use Program

If you're ineligible for clinical trials, Exelixis offers an expanded access (compassionate use) program that provides Zanzalintinib at no cost.

Eligibility Criteria

Your oncologist must document that you meet all these requirements:

  • Life-threatening cancer with no comparable approved therapies available
  • Exhausted standard treatments or cannot tolerate them (document specific prior therapies, dates, responses, and reasons for discontinuation)
  • ECOG performance status 0-2 with adequate organ function
  • Potential benefit outweighs risks in the physician's clinical judgment
  • Ineligible for available clinical trials

Application Process

  1. Oncologist initiates: Contact Exelixis medical affairs or visit Exelixis Medical Affairs
  2. FDA submission: Physician files FDA Form 3926 (single-patient IND)
  3. Documentation required:
    • Pathology and molecular reports
    • Recent imaging and staging
    • Complete treatment history
    • Risk-benefit assessment
  4. Timeline: 2-4 weeks typical; expedited processing available for emergencies

When Humana Denies Routine Care

Even with free drug through compassionate use, Humana may deny coverage for monitoring labs, imaging, or administration costs. Common denial reasons include:

  • "Investigational/experimental treatment not covered"
  • "Medical necessity not established"
  • "Prior authorization required but not obtained"

Your Appeal Rights with Humana

You have 65 days from the denial notice to file an appeal with Humana Medicare Advantage. Submit appeals through:

Decision Timeline: Humana must respond within 30 days for pre-service appeals or 60 days for post-service appeals.

New Jersey Appeals Process

New Jersey offers robust external review rights through the Independent Health Care Appeals Program (IHCAP), administered by Maximus Federal Services.

When You Can Use IHCAP

  • You've completed Humana's internal appeals process
  • The denial involves medical necessity for routine care (not the investigational drug itself)
  • You file within 4 months of Humana's final denial

How to File

Submit your external appeal at njihcap.maximus.com or call for forms. Required documents:

  • Completed IHCAP application
  • All denial letters from Humana
  • Medical records supporting necessity
  • Physician statement explaining why monitoring/care is medically necessary
  • Authorization for medical record release

Timeline

Review Type Decision Deadline When to Use
Standard Review 45 calendar days Routine appeals
Expedited Review 48 hours Urgent cases where delay could cause serious harm

Cost: Free to you—insurers pay all review costs.

From our advocates: We've seen patients succeed in IHCAP appeals by clearly separating the free investigational drug from the standard-of-care monitoring that any cancer patient would need. Frame your appeal around the routine medical care, not the experimental therapy itself.

Building Your Medical Necessity Case

Whether appealing to Humana or filing with IHCAP, your medical necessity letter should address these key points:

Essential Elements

  1. Diagnosis and staging with specific ICD-10 codes
  2. Treatment history - chronological list of prior therapies, responses, and reasons for discontinuation
  3. Clinical rationale - why monitoring/supportive care is necessary regardless of the investigational drug
  4. Standard of care alignment - cite NCCN guidelines for your cancer type regarding appropriate monitoring
  5. Risk without coverage - potential harm from delayed or inadequate monitoring

Supporting Documentation

  • Recent imaging and lab results
  • Pathology reports
  • Prior treatment records with dates and outcomes
  • FDA compassionate use approval letter
  • Relevant medical literature (peer-reviewed studies)

Templates and Scripts

Patient Phone Script for Humana

"Hello, I'm calling about a prior authorization denial for monitoring care related to my cancer treatment. My member ID is [ID]. I'm participating in an FDA-approved compassionate use program for an investigational cancer drug, and I need coverage for the routine medical care and monitoring that any cancer patient would require. Can you help me understand the appeals process and what documentation you need?"

Medical Necessity Letter Framework

Opening: "I am writing to request coverage for medically necessary monitoring and supportive care for [Patient Name], who has [diagnosis] and is participating in an FDA-approved expanded access program."

Body: Document prior treatments, current clinical status, and specific monitoring needs (labs, imaging, administration) with frequency and medical rationale.

Closing: "The requested monitoring represents standard oncology care that would be necessary regardless of the specific therapy. I respectfully request your reconsideration of this denial."

Costs and Patient Support

What's Free vs. What You Pay

  • Free: Zanzalintinib drug through trials or compassionate use
  • Potentially covered: Routine cancer care, monitoring, supportive medications
  • Your responsibility: Copays for covered services, travel to treatment centers

Additional Support Resources

  • Exelixis Patient Support: Contact through medical affairs for assistance with compassionate use applications
  • Cancer Financial Assistance: Organizations like CancerCare and Patient Access Network Foundation may help with copays for covered services
  • New Jersey Resources: Contact DOBI Consumer Hotline at 1-800-446-7467 for insurance questions

Frequently Asked Questions

How long does Humana take to make prior authorization decisions? Standard requests: 30 days for pre-service, 60 days for post-service. Expedited requests: 72 hours for pre-service, 24 hours for post-service.

What if Zanzalintinib becomes FDA-approved while I'm on treatment? Contact Humana immediately to request formulary coverage. Approval typically improves coverage prospects significantly.

Can I request an expedited appeal? Yes, if delaying care could seriously jeopardize your health. Check the "expedited" box on appeal forms and provide supporting documentation from your physician.

Does New Jersey's external review apply to Medicare Advantage? IHCAP covers some Medicare Advantage denials, but federal Medicare appeal rights may also apply. Consult with Humana or DOBI to determine the best path.

What happens if both Humana and IHCAP deny my appeal? For Medicare Advantage, you may have additional federal appeal levels. For other coverage, consider filing a complaint with DOBI or seeking legal assistance.

How do I find clinical trials near me in New Jersey? Search ClinicalTrials.gov by location, or contact major cancer centers like Rutgers Cancer Institute, Atlantic Health, or Hackensack Meridian Health.

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed rebuttals. Our platform helps patients, clinicians, and pharmacies navigate complex prior authorization requirements and build compelling cases for coverage. Learn more about our services.

Sources & Further Reading

This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for personalized guidance. Coverage policies and appeal procedures may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.